Renal Injury and Adaptation to Heme Proteins
Renal Injury and Adaptation to Heme Proteins
批准号:
7903739
负责人:
KARL A. NATH
金额:
$9.96万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-22 至 2011-08-31
关键词:
AcuteAdverse effectsAnti-Inflammatory AgentsAnti-inflammatoryApoptosisBilirubinBiliverdin reductaseBiliverdineBlood CirculationCCL2 geneCarbon MonoxideCouplingDevelopmentDiseaseEndothelin-1FundingGenerationsHeartHemeHemeproteinsInflammationInflammatory ResponseInjuryInterleukin-6IronIschemiaKidneyKidney DiseasesLaboratoriesMediatingModelingMusNADPH OxidaseOxygenasesPathway interactionsProteinsRegulationRoleSerumSignal TransductionSourceSuperoxidesSystemTNF genebasecytokineheme oxygenase-1heme oxygenase-2hemodynamicsinsightmortalityoverexpressionrenal ischemiavasoconstriction
中文摘要
血红素加氧酶(HO)将血红素转化为胆绿素,在此期间释放铁和一氧化碳。
(CO)胆绿素还原酶随后将胆绿素转化为胆红素。In 1992,the Pi's Pi 'laboratory实验室
提供了HO-1具有细胞保护作用的第一个证据,这一发现来源于急性肾血红素介导的
这是1993-1997年供资周期的基础; 1997-2002年周期是根据
Pi的实验室发现HO-1在其他形式的肾损伤中具有细胞保护作用。2002-2007年
循环试图确定被HO-1中断的致病途径,并证明,沿着相关的
HO系统抑制:i)血管收缩/缺血,i i)炎症,和iii)
凋亡拟议的目标延续了这些调查主题。目的我会阐述民政事务总署的角色
通过检查全身和肾脏血液动力学效应,
在HO-1+和HO-2+小鼠中的Ang II依赖性和Ang II非依赖性血管收缩(DOCA模型)。
这一目标将研究NADPH氧化酶,超氧阴离子生成,BH 4/BH 2水平等机制
和eNOS的偶联,以及内皮素-1的作用;这一目标也将决定产物在多大程度上
HO-1或HO-2缺乏时,HO的表达可逆转血管收缩反应的增强。目标二将决定
HO系统对LPS诱导的炎症的抗炎作用的基础是,
NF-κ B的活化是HO抗炎作用的关键位点。这些研究将决定
HO-1通过改变NF-κ B的活化调节炎症反应的程度;
特异性NF-κ B依赖性细胞因子(MCP-1、IL-6、IL-12(p40)和TNF)对过度的
由于HO-1缺乏引起的炎症;特定HO产物的抗炎能力以及是否
这些产物影响NF-κ B的活化;最后,HO-1过表达抑制LPS的能力,
驱动炎症。目的III将研究细胞凋亡、急性肾损伤和死亡率增加的基础
在HO-1小鼠中,进行肾缺血,重点是IL-6及其信号种类,pSTAT 3r。
现在被鉴定为肾脏中的促凋亡基因。IL-6在肾脏中被显著且独特地诱导,
心脏,并在血清中增加。在这种凋亡模型中,抑制IL-6/pSTAT 3的作用将被抑制。
测定这一目的也将确定IL-6在肾脏和体循环中的来源,
HO-1对IL-6表达的调控。因此,这一目标将确定IL-6、STAT-3、
细胞凋亡和其他不利影响的缺血在没有HO-1,和往复作用
IL-6和HO-1的细胞表达和信号传导之间的关系。总结。本申请旨在
了解一种叫做血红素氧合酶-1的蛋白质如何保护肾脏免受不同类型的疾病的侵害。
这种理解可能有助于开发肾脏疾病的新疗法。
英文摘要
Heme oxygenase (HO) converts heme to biliverdin during which iron is released and carbon monoxide
(CO) is emitted; biliverdin reductase subsequently converts biliverdin to bilirubin. In 1992, the Pi'slaboratory
provided the first evidence that HO-1 was cytoprotective, a finding derived in acute renal heme-mediated
injury, and which was the basis for the 1993-1997 funding cycle; the 1997-2002 cycle was based on the
finding by the Pi's laboratory that HO-1 was cytoprotective in other forms of renal injury. The 2002-2007
cycle sought to identify pathogenetic pathways interrupted by HO-1, and demonstrated, along with relevant
mechanistic insights, that the HO system inhibits: i) vasoconstriction/ischemia, li) inflammation, and iii)
apoptosis. The proposed aims continue these investigative themes. Aim I will delineate the role of the HO
system in militating against vasoconstriction by examining the systemic and renal hemodynamic effects of
Ang ll-dependent and Ang ll-independent vasoconstriction (theDOCA model) in HO-1"'" and HO^" mice.
This aim will examine such mechanisms as NADPH oxidase, superoxide anion generation, BH4/BH2 levels
and coupling of eNOS, and the role of endothelin-1; this aim will also determine the extent to which products
of HO can reverse the enhanced vasoconstriction when HO-1 or HO-2 is deficient. Aim II will determine the
basis for the anti-inflammatory effect of the HO system against LPS-induced_inflammation, targeting
activation of NF-KB as a critical locus for the anti-inflammatory effects of HO. These studies will determine
the following: the extent to which HO-1 regulates inflammatory responses by altering activation of NF-KB;the
contribution of specific NF-KB-dependent cytokines (MCP-1, IL-6,IL-12(p40), and TNF) to the exaggerated
inflammation due to HO-1 deficiency; the anti-inflammatory capacity of specific HO products and whether
such products influence NF-KB activation; and finally, the capacity of HO-1 overexpression to inhibit LPS-
driven inflammation. Aim III will examine the basis for apoptosis, acute renal injury, and increased mortality
in HO-1"'" mice, subjected to renal ischemia, focusing on IL-6 and its signaling species, pSTAT3rthe .latter
now identified as proapoptotic in the kidney. IL-6is markedly and uniquely induced in the kidney, Iung7 arid
heart, and increased in the serum. In this model of apoptosis, the effect of inhibiting IL-6/pSTAT3 will Jbe
determined. This aim will also determine th$ source of IL-6 in the kidney and systemic circulation, arid the
regulation of IL-6expression by HO-1. This aim will thus determine the contribution of IL-6^'STAT-3^
apoptosis and other adverse effects of ischemia in the absence of HO-1, and the reciprocating effects
between cellular expression and signaling of IL-6and HO-1. Lav Summary. This application seeks to
understand how a protein called heme oxygenase-1 protects the kidney against different types of diseases.
This understanding may facilitate the development of new therapies for kidney disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heme-mediated Mitochondrial Injury, Senescence, Acute Kidney Injury and Chronic Kidney Disease
-
批准号:10656648
-
项目类别:
-
资助金额:$59.92万
-
财政年份:2023
-
负责人:KARL A. NATH
-
依托单位:
The Murine Dialysis Fistula Model Exhibits a Senescence Phenotype: Pathobiologic Mechanisms and Therapeutic Potential
-
批准号:10301011
-
项目类别:
-
资助金额:$42.75万
-
财政年份:2018
-
负责人:KARL A. NATH
-
依托单位:
The Murine Dialysis Fistula Model Exhibits a Senescence Phenotype: Pathobiologic Mechanisms and Therapeutic Potential
-
批准号:10062970
-
项目类别:
-
资助金额:$42.75万
-
财政年份:2018
-
负责人:KARL A. NATH
-
依托单位:
Renal Vascular Injury
-
批准号:7226092
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2006
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:8212677
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:8334635
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:7565999
-
项目类别:
-
资助金额:$32.21万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:7341127
-
项目类别:
-
资助金额:$32.21万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:8919337
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:8537419
-
项目类别:
-
资助金额:$33.1万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:7013665
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:7172992
-
项目类别:
-
资助金额:$32.87万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
Mechanism of Dialysis Arteriovenous Fistula Dysfunction
-
批准号:6866077
-
项目类别:
-
资助金额:$34.66万
-
财政年份:2005
-
负责人:KARL A. NATH
-
依托单位:
The Role of Dendritic Cells in Renal Immune Responses
-
批准号:7248778
-
项目类别:
-
资助金额:$30.77万
-
财政年份:2004
-
负责人:KARL A. NATH
-
依托单位:
RENAL INJURY
-
批准号:6581191
-
项目类别:
-
资助金额:$15.09万
-
财政年份:2002
-
负责人:KARL A. NATH
-
依托单位:
RENAL INJURY
-
批准号:6202436
-
项目类别:
-
资助金额:$15.09万
-
财政年份:1999
-
负责人:KARL A. NATH
-
依托单位:
RENAL INJURY
-
批准号:6110589
-
项目类别:
-
资助金额:$15.09万
-
财政年份:1998
-
负责人:KARL A. NATH
-
依托单位:
RENAL INJURY
-
批准号:6242583
-
项目类别:
-
资助金额:$14.43万
-
财政年份:1997
-
负责人:KARL A. NATH
-
依托单位:
RENAL INJURY AND ADAPTATION TO HEME PROTEINS
-
批准号:2749498
-
项目类别:
-
资助金额:$22.62万
-
财政年份:1993
-
负责人:KARL A. NATH
-
依托单位:
RENAL INJURY AND ADAPTATION TO HEME PROTEINS
-
批准号:2905581
-
项目类别:
-
资助金额:$22.97万
-
财政年份:1993
-
负责人:KARL A. NATH
-
依托单位:
海外基金